-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, February 23.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
Source: CDE official website
Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Medical Network, February 23.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
Source: CDE official website
Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Medical Network, February 23.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
The original research company of this product is Bayer.
In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
3 billion yuan.
Currently, only original research is imported in China.
Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
Source: CDE official website
Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
Hospital hospital hospitalcom, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
In the first half of 2020, affected by the epidemic, the sales scale declined.
The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
The injection is expected to hit the first reviewer.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
